Robert W. Baird Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $15.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective trimmed by Robert W. Baird from $21.00 to $15.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts have also weighed in on KPTI. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating for the company. Piper Sandler reissued an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.86.

Karyopharm Therapeutics Trading Down 1.6%

Karyopharm Therapeutics stock opened at $5.48 on Wednesday. The firm has a market cap of $100.50 million, a price-to-earnings ratio of -0.33 and a beta of 0.13. The stock has a fifty day simple moving average of $7.72 and a two-hundred day simple moving average of $6.82. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to the consensus estimate of $33.16 million. On average, equities research analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. boosted its position in Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after purchasing an additional 790,417 shares during the last quarter. Ikarian Capital LLC increased its position in shares of Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after purchasing an additional 517,297 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares during the period. Bank of America Corp DE lifted its stake in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Finally, Boothbay Fund Management LLC bought a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $1,064,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics News Summary

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm announced a new equity financing that should bolster liquidity and extend runway, easing short‑term funding risk. Karyopharm Strengthens Liquidity With New Equity Financing
• Positive Sentiment: HC Wainwright raised its EPS forecasts across multiple quarters and reiterated a “Buy” rating with an $8 price target — the analyst upgrades signal improved near‑term expectations for operating performance. MarketBeat HC Wainwright Coverage
• Neutral Sentiment: Zacks noted that KPTI shares jumped ~6.9% on above‑average volume recently but also warned that the recent trend in earnings‑estimate revisions doesn’t strongly support further upside. Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
• Negative Sentiment: A Seeking Alpha analysis contextualized mixed Phase 3 SENTRY results for selinexor (met spleen endpoint but missed symptom endpoint), highlighted an immature overall‑survival signal, and emphasized a tight cash runway — even after a $30M private placement — leaving existential funding risk if additional financing is delayed or unfavorable. Karyopharm: Putting The Phase 3 Trial In Context
• Negative Sentiment: Robert W. Baird published a bearish/pessimistic forecast for KPTI’s stock price, adding downside analyst pressure and signaling investor caution. Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.